Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
General Atlantic backs OSEA Malibu as clean beauty brand eyes global expansion
General Atlantic backs OSEA Malibu as clean beauty brand eyes global expansion General Atlantic has agreed to make a strategic growth investment in OSEA Malibu, the US-based clean skincare brand, enabling the company to expand globally and strengthen its product...
Five Arrows tops €2.4bn close for latest debt fund, 70% larger than predecessor
Five Arrows tops €2.4bn close for latest debt fund, 70% larger than predecessor Five Arrows, the alternative assets arm of Rothschild & Co, has closed Five Arrows Debt Partners IV (FADP IV) at €2.4bn, exceeding its €2bn target and marking a more than 70% increase...
Blackstone and TPG reignite talks on $15bn-plus Hologic buyout
Blackstone and TPG reignite talks on $15bn-plus Hologic buyout Blackstone and TPG have revived their interest in acquiring Hologic, the US-based women’s health diagnostics company, in what could become one of the largest healthcare buyouts of 2025, according to...